Management of Hodgkin Lymphoma Status Post Autologous Hematopoietic Stem Cell Transplantation
Originally presented at HOPA's 13th Annual Conference, March 2017.
Although aHSCT is the standard of care for patients with relapsed HL, only about 50% of these patients will be cured. Patients who relapse or have progressive disease after aHSCT have a very poor prognosis. This session will focus on risk factors associated with disease relapse following aHSCT and the use of brentuximab vedotin as consolidation treatment in high-risk patients. The use of novel agents such as PD-1 inhibitors in patients who relapse post aHSCT will also be discussed.
- Identify risk factors associated with relapse after autologous hematopoietic stem cell transplant (aHSCT) in patients with Hodgkin lymphoma (HL).
- Review the role of consolidation therapy with brentuximab vedotin status post aHSCT.
- Describe novel treatments for patients with relapsed HL status post aHSCT.
Sandra Horowitz, PharmD
Sandra Horowitz, is clinical pharmacy specialist in the Division of Pharmacy at the University of Texas MD Anderson Cancer Center in Houston and has been practicing in lymphoma and myeloma since 2000. She received her bachelor of science and PharmD degrees from St. John’s University in Jamaica, NY, and completed a PGY-2 oncology pharmacy residency at the University of Texas MD Anderson Cancer Center.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020